Latest News and Press Releases
Want to stay updated on the latest news?
-
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming...
-
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
-
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Workforce Engagement Management, 2025" report has been added to ResearchAndMarkets.com's offering.A Benchmarking System to Spark...
-
Toronto, ON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Applied Systems® today announced the fourth quarter of 2025 results of the Applied Rating Index™, the Canadian insurance industry’s premium rate index....
-
Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Understanding and Managing Contracts to Achieve Better Results Training Course (April 15-16, 2026)" training has been added to ...
-
Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Real Estate Ownership and Leasing of Agricultural, Timber and Similar Lands (U.S.) Financial Analysis, Market Size & Benchmarks, and Revenue...
-
Dublin, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The "Remodeling Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global remodeling market is on track for substantial...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Alexandria Real Estate Equities, Inc. Class Action Deadline January 26 – Investors Notified to Contact BFA Law to Protect Your Rights
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...